This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
by Zacks Equity Research
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 26.03% and 4.97%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
BioMarin to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.
SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
by Zacks Equity Research
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
by Zacks Equity Research
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
by Zacks Equity Research
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
by Zacks Equity Research
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
by Zacks Equity Research
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
by Zacks Equity Research
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
by Zacks Equity Research
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
3 Reasons Growth Investors Will Love BioMarin (BMRN)
by Zacks Equity Research
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks.com featured highlights BioMarin, Cheesecake Factory, Leidos and The Ensign
by Zacks Equity Research
BioMarin, Cheesecake Factory, Leidos and The Ensign have been highlighted in this Screen of The Week article.
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi
by Zacks Equity Research
The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.